Focus: Ion Dx is a public biotechnology company founded in 2019 specializing in ion mobility spectrometer technology and associated services, operating across neurology, ophthalmology, gastroenterology, and musculoskeletal therapeutic areas. The company is actively recruiting with 82 open positions, suggesting active expansion despite limited public visibility.
Profile data last refreshed 1h ago · AI intelligence enriched 1w ago
Hot — 83 jobs added in 30d
Net +66 (83 new, 17 removed). Aggressive expansion phase.
Ion Dx offers growth and diversification in an emerging technology space, but lack of clinical pipeline transparency and financial disclosure presents career risk for those seeking established drug-development or revenue-generating roles.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Ion Dx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ion Dx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo